LUCY Glenn appeared “completely healthy” until she was 18 months old when her behaviour suddenly changed. Her mum, Katherine McCready, 31, said noticed she suddenly stopped playing ...
NGNE to update on a potential registrational phase 3 study, using NGN-401, for the treatment of patients with Rett Syndrome.
Rett syndrome is a devastating neurological disorder ... such as epileptic seizures. In the phase 1/2 trial, the first four patients all achieved a "much improved" rating on the clinician-rated ...
Minoryx Therapeutics has dosed the first patient in its phase 2a TREE study, which evaluates the safety and efficacy of ...
AZoLifeSciences on MSN15d
Minoryx Announces Dosing of the First Patient with Leriglitazone in the Phase 2a Study in Rett Syndrome (TREE Study)Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system ...
Biomed Industries, Inc. Biomed pipeline Biomed Industries, Inc. to Announce Phase 2/3 Results of NA-921 for the Treatment of Rett Sy ...
The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in children two to four years of age as that observed in individuals with Rett syndrome five years of age and older ...
The study, which included 15 patients, demonstrated that DAYBUE maintained a similar safety profile in younger pediatric patients as seen in older patients in previous Phase 3 studies. The ...
Minoryx Therapeutics has dosed the first patient in its phase 2a TREE study, which evaluates the safety and efficacy of leriglitazone in treating Rett syndrome. The trial involves 24 female patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback